FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2738420121> ?p ?o ?g. }

• W2738420121 endingPage "69915" @default.
• W2738420121 startingPage "69906" @default.
• W2738420121 abstract "// Satoshi Imanishi 1 , Ryoko Takahashi 1 , Seiichiro Katagiri 2 , Chiaki Kobayashi 1, 2 , Tomohiro Umezu 1, 2 , Kazuma Ohyashiki 2 and Junko H. Ohyashiki 1 1 Department of Molecular Oncology, Institute for Medical Science, Tokyo Medical University, Nishi-Shinjuku, Shinjuku, Tokyo, Japan 2 Department of Hematology, Tokyo Medical University, Nishi-Shinjuku, Shinjuku, Tokyo, Japan Correspondence to: Satoshi Imanishi, email: s-ima@tokyo-med.ac.jp Keywords: azacytidine, teriflunomide, pyrimidine metabolism, sensitization Abbreviations: AZA, azacytidine; UCK, uridine cytidine kinase; DNMT, DNA methyltransferase; MDS, myelodysplastic syndromes; AML, acute myeloid leukemia Received: November 09, 2016      Accepted: June 19, 2017      Published: July 22, 2017 ABSTRACT Previous studies showed that downregulation of pyrimidine salvage underlies resistance against 5-azacytidine (AZA), indicating an important role for de novo pyrimidine synthesis in AZA resistance. Because de novo pyrimidine synthesis is inhibited by the immunomodulator teriflunomide and its pro-drug leflunomide, we examined the effect of combined treatment with AZA and teriflunomide on AZA resistance to develop a novel strategy to cancel and prevent AZA resistance. Teriflunomide markedly inhibited the growth of AZA-resistant human leukemia cell lines (R-U937 and R-HL-60) in comparison with their AZA-sensitive counterparts (U937 and HL-60). In the presence of a non-toxic concentration of teriflunomide (1 μM), AZA induced apoptosis in AZA-resistant cells and leukemia cells from AZA-resistant patients. AZA acted as a DNA methyltransferase 3A inhibitor in AZA-resistant cells in the presence of 1 μM teriflunomide. Although AZA-sensitive cells acquired AZA resistance after continuous treatment with AZA for 42 days, the growth of AZA-sensitive cells continuously treated with the combination of AZA and teriflunomide was significantly inhibited in the presence of AZA, demonstrating that the combined treatment prevented AZA resistance. These results suggest that combined treatment with AZA and teriflunomide can be a novel strategy to overcome AZA resistance." @default.
• W2738420121 created "2017-07-31" @default.
• W2738420121 creator A5004117271 @default.
• W2738420121 creator A5009403998 @default.
• W2738420121 creator A5019513106 @default.
• W2738420121 creator A5022851085 @default.
• W2738420121 creator A5023748277 @default.
• W2738420121 creator A5045789460 @default.
• W2738420121 creator A5053689963 @default.
• W2738420121 date "2017-07-22" @default.
• W2738420121 modified "2023-09-27" @default.
• W2738420121 title "Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells" @default.
• W2738420121 cites W1602576891 @default.
• W2738420121 cites W1947502830 @default.
• W2738420121 cites W1968240894 @default.
• W2738420121 cites W1977282213 @default.
• W2738420121 cites W1983382084 @default.
• W2738420121 cites W1985704394 @default.
• W2738420121 cites W1985761301 @default.
• W2738420121 cites W2017394727 @default.
• W2738420121 cites W2029200519 @default.
• W2738420121 cites W2038599275 @default.
• W2738420121 cites W2049982892 @default.
• W2738420121 cites W2061711005 @default.
• W2738420121 cites W2067326892 @default.
• W2738420121 cites W2076393800 @default.
• W2738420121 cites W2080270409 @default.
• W2738420121 cites W2081694922 @default.
• W2738420121 cites W2096439168 @default.
• W2738420121 cites W2106121989 @default.
• W2738420121 cites W2118771330 @default.
• W2738420121 cites W2131593570 @default.
• W2738420121 cites W2136817553 @default.
• W2738420121 cites W2152151928 @default.
• W2738420121 cites W2157287007 @default.
• W2738420121 cites W2160699404 @default.
• W2738420121 cites W2172137514 @default.
• W2738420121 cites W4232645703 @default.
• W2738420121 doi "https://doi.org/10.18632/oncotarget.19436" @default.
• W2738420121 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5642525" @default.
• W2738420121 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29050250" @default.
• W2738420121 hasPublicationYear "2017" @default.
• W2738420121 type Work @default.
• W2738420121 sameAs 2738420121 @default.
• W2738420121 citedByCount "8" @default.
• W2738420121 countsByYear W27384201212019 @default.
• W2738420121 countsByYear W27384201212020 @default.
• W2738420121 countsByYear W27384201212021 @default.
• W2738420121 countsByYear W27384201212022 @default.
• W2738420121 countsByYear W27384201212023 @default.
• W2738420121 crossrefType "journal-article" @default.
• W2738420121 hasAuthorship W2738420121A5004117271 @default.
• W2738420121 hasAuthorship W2738420121A5009403998 @default.
• W2738420121 hasAuthorship W2738420121A5019513106 @default.
• W2738420121 hasAuthorship W2738420121A5022851085 @default.
• W2738420121 hasAuthorship W2738420121A5023748277 @default.
• W2738420121 hasAuthorship W2738420121A5045789460 @default.
• W2738420121 hasAuthorship W2738420121A5053689963 @default.
• W2738420121 hasBestOaLocation W27384201211 @default.
• W2738420121 hasConcept C104317684 @default.
• W2738420121 hasConcept C126322002 @default.
• W2738420121 hasConcept C150194340 @default.
• W2738420121 hasConcept C181199279 @default.
• W2738420121 hasConcept C185592680 @default.
• W2738420121 hasConcept C190727270 @default.
• W2738420121 hasConcept C200159599 @default.
• W2738420121 hasConcept C203014093 @default.
• W2738420121 hasConcept C2775905006 @default.
• W2738420121 hasConcept C2776036978 @default.
• W2738420121 hasConcept C2776239401 @default.
• W2738420121 hasConcept C2776476023 @default.
• W2738420121 hasConcept C2776694085 @default.
• W2738420121 hasConcept C2777703276 @default.
• W2738420121 hasConcept C2777844706 @default.
• W2738420121 hasConcept C2778461978 @default.
• W2738420121 hasConcept C2779268695 @default.
• W2738420121 hasConcept C2780007613 @default.
• W2738420121 hasConcept C2780258809 @default.
• W2738420121 hasConcept C2780640218 @default.
• W2738420121 hasConcept C2780817109 @default.
• W2738420121 hasConcept C2781059491 @default.
• W2738420121 hasConcept C502942594 @default.
• W2738420121 hasConcept C55493867 @default.
• W2738420121 hasConcept C71924100 @default.
• W2738420121 hasConcept C98274493 @default.
• W2738420121 hasConceptScore W2738420121C104317684 @default.
• W2738420121 hasConceptScore W2738420121C126322002 @default.
• W2738420121 hasConceptScore W2738420121C150194340 @default.
• W2738420121 hasConceptScore W2738420121C181199279 @default.
• W2738420121 hasConceptScore W2738420121C185592680 @default.
• W2738420121 hasConceptScore W2738420121C190727270 @default.
• W2738420121 hasConceptScore W2738420121C200159599 @default.
• W2738420121 hasConceptScore W2738420121C203014093 @default.
• W2738420121 hasConceptScore W2738420121C2775905006 @default.
• W2738420121 hasConceptScore W2738420121C2776036978 @default.
• W2738420121 hasConceptScore W2738420121C2776239401 @default.
• W2738420121 hasConceptScore W2738420121C2776476023 @default.
• W2738420121 hasConceptScore W2738420121C2776694085 @default.

• next